Xenon Pharmaceuticals Inc.
XENE
$42.88
-$0.63-1.45%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.31% | -30.22% | 0.97% | -4.61% | -8.40% |
| Total Depreciation and Amortization | 1.42% | -4.10% | 4.11% | -5.10% | 4.06% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -21.36% | 15.32% | 76.08% | -38.03% | -16.24% |
| Change in Net Operating Assets | 89.21% | 121.51% | -657.31% | 278.76% | -112.49% |
| Cash from Operations | -11.71% | -4.19% | -13.36% | -9.50% | -59.43% |
| Capital Expenditure | -78.98% | -265.12% | 94.51% | -32.71% | 61.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -52.91% | 138.52% | -65.20% | 9,025.55% | -99.02% |
| Cash from Investing | -53.16% | 138.37% | -64.97% | 19,679.72% | -99.54% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,530.77% | -94.35% | -90.51% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 3,530.77% | -94.35% | -90.51% | -- | -- |
| Foreign Exchange rate Adjustments | -100.95% | 1,087.50% | 94.47% | -2,242.59% | 126.73% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -264.85% | 171.86% | -147.29% | 212.17% | -163.10% |